[go: up one dir, main page]

IL113851A - Continuous method of grinding pharmaceutical substances - Google Patents

Continuous method of grinding pharmaceutical substances

Info

Publication number
IL113851A
IL113851A IL11385195A IL11385195A IL113851A IL 113851 A IL113851 A IL 113851A IL 11385195 A IL11385195 A IL 11385195A IL 11385195 A IL11385195 A IL 11385195A IL 113851 A IL113851 A IL 113851A
Authority
IL
Israel
Prior art keywords
agent
grinding media
milling chamber
particle size
grinding
Prior art date
Application number
IL11385195A
Other languages
English (en)
Other versions
IL113851A0 (en
Original Assignee
Nanosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanosystems Llc filed Critical Nanosystems Llc
Publication of IL113851A0 publication Critical patent/IL113851A0/xx
Publication of IL113851A publication Critical patent/IL113851A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/888—Shaping or removal of materials, e.g. etching
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/90—Manufacture, treatment, or detection of nanostructure having step or means utilizing mechanical or thermal property, e.g. pressure, heat
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Crushing And Pulverization Processes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Disintegrating Or Milling (AREA)
IL11385195A 1994-05-25 1995-05-25 Continuous method of grinding pharmaceutical substances IL113851A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/249,787 US5718388A (en) 1994-05-25 1994-05-25 Continuous method of grinding pharmaceutical substances

Publications (2)

Publication Number Publication Date
IL113851A0 IL113851A0 (en) 1995-08-31
IL113851A true IL113851A (en) 1999-12-22

Family

ID=22944996

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11385195A IL113851A (en) 1994-05-25 1995-05-25 Continuous method of grinding pharmaceutical substances

Country Status (14)

Country Link
US (1) US5718388A (xx)
EP (1) EP0804161B1 (xx)
JP (1) JP3607294B2 (xx)
AT (1) ATE208191T1 (xx)
AU (1) AU2476195A (xx)
CA (1) CA2190134C (xx)
DE (1) DE69523781T2 (xx)
DK (1) DK0804161T3 (xx)
ES (1) ES2165913T3 (xx)
IL (1) IL113851A (xx)
MY (1) MY113569A (xx)
PT (1) PT804161E (xx)
TW (1) TW460297B (xx)
WO (1) WO1995031973A1 (xx)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213638C (en) * 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US6832735B2 (en) * 2002-01-03 2004-12-21 Nanoproducts Corporation Post-processed nanoscale powders and method for such post-processing
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6000646A (en) * 1998-03-16 1999-12-14 Ranne; Bethyl H. Double barrel media mill for grinding and dispersing particulate matter and pigment for paint, coatings, ink and other fluid pigment vehicles
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6444223B1 (en) 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
AU5300000A (en) * 1999-06-01 2000-12-18 Elan Pharma International Limited Small-scale mill and method thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
ES2334435T3 (es) 2000-04-26 2010-03-10 Elan Pharma International Limited Aparato de molienda humeda higienica.
CN1211164C (zh) 2000-05-10 2005-07-20 斯凯伊药品加拿大公司 介质研磨
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
EP1313451B1 (en) 2000-08-31 2009-03-11 Jagotec AG Milled particles
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
HU230435B1 (hu) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (sr) * 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
DE60123844T2 (de) * 2001-04-27 2007-08-30 Kansai Paint Co., Ltd., Amagasaki Verfahren und vorrichtung zum dispergieren von farbstoffen in einem flüssigen medium
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
DE60203506T2 (de) * 2001-06-22 2006-02-16 Marie Lindner Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
US7758890B2 (en) * 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US6722699B2 (en) * 2001-08-02 2004-04-20 Eastman Kodak Company Authentication using near-field optical imaging
US8403367B2 (en) 2001-08-02 2013-03-26 Eastman Kodak Company Authentication using near-field optical imaging
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030095928A1 (en) * 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
EP1443912B1 (en) * 2001-10-12 2007-08-29 Elan Pharma International Limited Compositions having a combination of immediate release and controlled release characteristics
EP1450863A4 (en) * 2001-11-07 2009-01-07 Imcor Pharmaceutical Company PROCESS FOR IMAGING VESSELS WITH NANOTEHTIC CONTAINERS
PL370889A1 (en) 2001-12-20 2005-05-30 Femmepharma, Inc. Vaginal delivery of drugs
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
CA2475092C (en) * 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
US6699963B2 (en) 2002-03-18 2004-03-02 The Procter & Gamble Company Grinding process for plastic material and compositions therefrom
WO2003080023A2 (en) * 2002-03-20 2003-10-02 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040076586A1 (en) * 2002-03-28 2004-04-22 Reinhard Koening Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
EP1494649B1 (en) 2002-04-12 2012-01-04 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1511467A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
CA2492488A1 (en) 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
ATE487470T1 (de) 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
WO2004033083A2 (en) * 2002-10-09 2004-04-22 Novozymes A/S A method for improving particle compositions
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
ATE514418T1 (de) * 2002-11-12 2011-07-15 Elan Pharma Int Ltd Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
US20040173696A1 (en) * 2002-12-17 2004-09-09 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
AU2004203700B2 (en) 2003-01-02 2007-06-21 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
CA2513064C (en) * 2003-01-31 2009-11-10 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
KR20060007372A (ko) * 2003-03-06 2006-01-24 렌슬러 폴리테크닉 인스티튜트 실온에서 벌크 고체로부터 나노입자를 고속 발생시키는방법
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2523035C (en) * 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
EP1651189B1 (en) * 2003-08-08 2008-12-03 Elan Pharma International Limited Novel metaxalone compositions
US7618181B2 (en) * 2003-10-23 2009-11-17 Kansai Paint Co., Ltd. Method for dispersing pigment in liquid medium
CA2544627A1 (en) * 2003-11-05 2005-05-19 Elan Pharma International Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
EP1621200A1 (en) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate
EA200701065A1 (ru) 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
MX2007007342A (es) * 2004-12-15 2007-12-11 Elan Pharma Int Ltd Formulaciones de tacrolimus nanoparticuladas.
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
CA2590386A1 (en) * 2004-12-30 2006-07-06 Cinvention Ag Combination comprising an agent providing a signal, an implant material and a drug
NZ555719A (en) * 2004-12-31 2010-11-26 Iceutica Pty Ltd Nanoparticle composition and methods for synthesis thereof
CN101132770A (zh) * 2005-01-06 2008-02-27 伊兰制药国际有限公司 纳米微粒坎地沙坦制剂
ATE412691T1 (de) * 2005-01-13 2008-11-15 Cinv Ag Kohlenstoffnanopartikel enthaltende verbundwerkstoffe
EP1841520A1 (en) * 2005-01-24 2007-10-10 Cinvention Ag Metal containing composite materials
MX2007009915A (es) 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
AU2006224582A1 (en) * 2005-03-18 2006-09-21 Cinvention Ag Process for the preparation of porous sintered metal materials
CA2602341A1 (en) * 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
MX2007012762A (es) 2005-04-12 2008-01-14 Elan Pharma Int Ltd Composiciones de material nanoparticulado y de liberacion controlada que comprende ciclosporina.
EP1871345B1 (en) * 2005-04-12 2012-08-01 Elan Pharma International Limited Nanoparticulate erlotinib formulations
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
BRPI0608771A2 (pt) * 2005-05-10 2010-01-26 Elan Pharma Int Ltd formulações de clopidogrel em nanopartìcula
EA200702518A1 (ru) * 2005-05-16 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции на основе наночастиц и с контролируемым высвобождением, включающие цефалоспорин
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
AU2006309295B2 (en) * 2005-06-03 2012-04-26 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
ATE459341T1 (de) 2005-06-03 2010-03-15 Elan Pharma Int Ltd Nanoteilchenförmige imatinib-mesylat- formulierungen
EP1954253A4 (en) 2005-06-08 2011-07-27 Elan Pharma Int Ltd NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
JP2008543766A (ja) * 2005-06-09 2008-12-04 エラン ファーマ インターナショナル リミテッド ナノ粒子エバスチン製剤
BRPI0611626A2 (pt) * 2005-06-13 2010-09-21 Elan Pharma Int Ltd formulações da combinação de nanopartìculas de clopidogrel e aspirina
JP2008543862A (ja) * 2005-06-15 2008-12-04 エラン ファーマ インターナショナル リミテッド ナノ粒子アゼルニジピン製剤
CA2612446A1 (en) * 2005-07-01 2007-01-11 Cinvention Ag Process for the production of porous reticulated composite materials
EA012091B1 (ru) * 2005-07-01 2009-08-28 Синвеншен Аг Медицинское устройство, содержащее сетчатый композиционный материал
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
GB0516549D0 (en) * 2005-08-12 2005-09-21 Sulaiman Brian Milling system
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
JP2009511727A (ja) * 2005-10-18 2009-03-19 シンベンション アーゲー 熱硬化粒子及びその製造方法
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
WO2007089335A2 (en) 2005-12-29 2007-08-09 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
EP2001439A2 (en) * 2006-03-07 2008-12-17 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
CN101495096A (zh) 2006-05-30 2009-07-29 伊兰制药国际有限公司 纳米微粒泊沙康唑制剂
WO2008000042A1 (en) 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
TW200820991A (en) * 2006-07-10 2008-05-16 Elan Pharma Int Ltd Nanoparticulate sorafenib formulations
BRPI0714173A2 (pt) * 2006-07-12 2012-12-25 Elan Pharma Int Ltd composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem
EP2101735A2 (en) 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
UA99270C2 (xx) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. Сполуки на основі 4-феніл-6-(2,2,2-трифтор-1-фенілетокси)піримідину і їх застосування$соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилетокси)пиримидина и их применение
CN101646402A (zh) * 2007-01-19 2010-02-10 金文申有限公司 用粉末模塑法制成的多孔、不可降解植入物
EP2129766A2 (en) * 2007-02-28 2009-12-09 Cinvention Ag High surface cultivation system with filler
CA2677721A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system with surface increasing substrate
BRPI0807993A2 (pt) * 2007-02-28 2014-06-17 Cinv Ag Sistema de cultivo de alta superfície.
WO2008104599A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system bag
CA2715422A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
CN102395378B (zh) 2009-02-18 2016-01-20 爱昂粒子科学有限责任公司 用于眼科和其他外用或局部应用的双功能共聚物
EP2448406B1 (en) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
WO2010138539A2 (en) 2009-05-27 2010-12-02 Elan Pharma International Ltd. Reduction of flake-like aggregation in nanoparticulate active agent compositions
US9044475B2 (en) 2009-06-12 2015-06-02 Cynapsus Therapeutics, Inc. Sublingual apomorphine
AU2010261509A1 (en) 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanoparticulate telmisartan compositions and process for the preparation thereof
HUP0900384A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
WO2010146407A1 (en) 2009-06-19 2010-12-23 Nanoform Hungary Ltd. Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
HUP0900376A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
JP2013510092A (ja) 2009-11-05 2013-03-21 レクシコン ファーマシューティカルズ インコーポレイテッド がんの治療のためのトリプトファンヒドロキシラーゼ阻害剤
JP2013519673A (ja) 2010-02-10 2013-05-30 レクシコン ファーマシューティカルズ インコーポレイテッド 転移性骨疾患の治療のためのトリプトファンヒドロキシラーゼ阻害剤
WO2011133980A1 (en) 2010-04-23 2011-10-27 Subhash Desai Therapeutic formulation for reduced drug side effects
US9511037B2 (en) 2010-04-23 2016-12-06 Genco Sciences Llc Compositions for reduction of side effects
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
HUP1000325A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
HUP1000327A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Composition containing nanostructured ezetibime and process for it's preparation
AU2011305567A1 (en) 2010-09-22 2013-05-02 Map Pharmaceuticals, Inc. Corticosteroid particles and method of production
DE102010052656B4 (de) * 2010-11-26 2025-08-21 Netzsch-Feinmahltechnik Gmbh Hydraulische mahlkugelzu- und abfuhr für rührwerkskugelmühlen
ES2791715T3 (es) 2010-12-16 2020-11-05 Sunovion Pharmaceuticals Inc Películas sublinguales
US9562015B2 (en) 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
US10022303B2 (en) * 2012-02-28 2018-07-17 Iceutica Pty Ltd. Inhalable pharmaceutical compositions
US20130303763A1 (en) 2012-03-30 2013-11-14 Michael D. Gershon Methods and compositions for the treatment of necrotizing enterocolitis
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166385A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
WO2014130612A1 (en) 2013-02-20 2014-08-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015020572B1 (pt) * 2013-02-28 2022-02-22 Sun Chemical Corporation Processo contínuo para transformar sólido moído em dispersão líquida e aparelho
BR112015032262A2 (pt) 2013-06-28 2017-07-25 Rexahn Pharmaceuticals Inc composições de nanopartículas e formulações de compostos de piperazina
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HU231309B1 (hu) 2014-02-25 2022-11-28 Darholding Kft. Nanostrukturált Indomethacint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás előállításukra
US20150343453A1 (en) * 2014-05-28 2015-12-03 NanoCentrix L.L.C. Fluid energy media mill system and method
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
BR112017002926A2 (pt) 2014-08-18 2017-12-12 Alkermes Pharma Ireland Ltd composições e método para aprimorar o perfil de liberação farmacocinético inicial in vivo
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
WO2016172095A1 (en) 2015-04-21 2016-10-27 Cynapsus Therapeutics, Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US10011629B2 (en) 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
EA036155B1 (ru) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Инъекционные составы нейростероида, содержащие наночастицы
CA3014788A1 (en) 2016-02-17 2017-08-24 Alkermes Pharma Ireland Limited Compositions of multiple aripiprazole prodrugs
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
RS63136B9 (sr) 2016-09-13 2022-10-31 Kyowa Kirin Co Ltd Lekoviti sastav koji sadrži tivozanib
CA3087192A1 (en) 2017-12-27 2019-07-04 Raymond F. Schinazi Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
WO2020041683A2 (en) 2018-08-23 2020-02-27 Sunovion Pharmaceuticals Inc. Acid addition salts of apomorphine, pharmaceutical compositions containing the same, and methods of using the same
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
EA202193251A1 (ru) 2019-06-05 2022-03-10 Эмори Юниверсити Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
CA3154437A1 (en) 2019-10-11 2021-04-15 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
EP3928772B1 (en) 2020-06-26 2024-06-19 Algiax Pharmaceuticals GmbH Nanoparticulate composition
JP2022052396A (ja) * 2020-09-23 2022-04-04 株式会社リコー 分散液の製造方法及び製造装置
CN112427096B (zh) * 2020-10-19 2022-01-28 上海旭军机械有限公司 一种纳米材料的研磨设备
CN116408192A (zh) * 2021-12-29 2023-07-11 南方科技大学 一种表界面调控法制备微纳米碳颗粒的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2595117A (en) * 1950-03-08 1952-04-29 Smidth & Co As F L Method and apparatus for grinding
ES293103A1 (es) * 1962-11-12 1964-03-16 Aziende Colori Naz Affini Acna S P A Procedimiento para la preparación de quinacridona en forma de pigmento
US3713593A (en) * 1970-08-11 1973-01-30 Freeport Sulphur Co Fine media milling process
SU514627A1 (ru) * 1972-07-19 1976-05-25 Институт Биохимии И Физиологии Микроорганизмов Ан Ссср Дезинтегратор дл микроорганизмов
US4860957A (en) * 1988-03-29 1989-08-29 Lidstroem Lars Treatment of middlings
JPH02132162A (ja) * 1988-11-11 1990-05-21 Showa Shell Sekiyu Kk 微小ジルコニア焼成ボールによる顔料の分散方法
US5174512A (en) * 1988-12-16 1992-12-29 Snamprogetti S.P.A. Grinding process and a continuous high-capacity micronizing mill for its implementation
JPH02196719A (ja) * 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
JPH04166246A (ja) * 1990-10-31 1992-06-12 Matsushita Electric Ind Co Ltd 媒体撹拌ミル及び粉砕方法
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
JPH05253509A (ja) * 1991-05-08 1993-10-05 Fuaimatetsuku:Kk 流通式媒体攪拌超微粉砕機
JPH05253512A (ja) * 1992-03-11 1993-10-05 Chuo Kakoki Kk 粉粒体又はスラリーの処理用媒体
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances

Also Published As

Publication number Publication date
DE69523781T2 (de) 2002-06-13
CA2190134C (en) 2005-03-08
ATE208191T1 (de) 2001-11-15
DK0804161T3 (da) 2002-03-04
ES2165913T3 (es) 2002-04-01
AU2476195A (en) 1995-12-18
PT804161E (pt) 2002-04-29
CA2190134A1 (en) 1995-11-30
WO1995031973A1 (en) 1995-11-30
IL113851A0 (en) 1995-08-31
JP3607294B2 (ja) 2005-01-05
JPH10500593A (ja) 1998-01-20
EP0804161B1 (en) 2001-11-07
EP0804161A1 (en) 1997-11-05
DE69523781D1 (de) 2001-12-13
MY113569A (en) 2002-04-30
TW460297B (en) 2001-10-21
US5718388A (en) 1998-02-17

Similar Documents

Publication Publication Date Title
IL113851A (en) Continuous method of grinding pharmaceutical substances
AU2550195A (en) Method of grinding pharmaceutical substances
WO2002045691A3 (en) Laboratory scale milling process
PL323444A1 (en) Method of and apparatus for elestrostatically charging particles suspended in fluid gaseous medium and separating them therefrom
CA2237310A1 (en) Process for separation and recovery of waste carpet components
AU2800395A (en) Method and apparatus for the formation of particles
CA2166301A1 (en) Method and apparatus for the formation of particles
SE9301395D0 (sv) Saett och anordning foer vaetskekromatografi
EG20603A (en) Method and apparatus for extracting with liquids soluble substances from subdivided solids
PL307354A1 (en) Treating apparatus
EP0853065A3 (en) Processing of ceramic materials
IN171515B (xx)
KR960700819A (ko) 지르코늄 실리케이트 연마 매체 및 분쇄 방법(zirconium silicate grinding medium and method of milling)
ZA955367B (en) Process for the extraction of a liquid contained in matter in particular from grapes and pressing apparatus to apply said process
JP3924733B2 (ja) 湿式媒体分散装置
CA2230953A1 (en) Advanced particulate media for precise separation of particles suspended in fluids
HU903176D0 (en) Liquid filter for separation of solid impurities, agglomerated grains of suspensions and other particles formed by settling out in liquids
JPS59154149A (ja) 固体粒子の粉砕法
HUT60643A (en) Method for filtering the dust content of air and air-filtering insert
Nakamura et al. Method for producing ultrafine particles
HK1001541A1 (en) Process and plant for separating husks from malt
CA2262746A1 (en) Method of and apparatus for separating solvent in a feed of solvent and deasphalted oil
JPS60250098A (ja) 石炭の脱灰法

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired